Inhibition of SIRTI combined with gemcitabine therapy for pancreatic carcinoma

Clinical Interventions in Aging

Volumn 8, Issue , 2013, Pages 889-897

  Gong, Dao Jun ^a   Zhang, Jia Min ^a   Yu, Min ^a   Zhuang, Bo ^a   Guo, Qing Qu ^b  

^a ZHEJIANG NORMAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Combination therapy; Inhibition of SIRT1 gemcitabine; Pancreatic carcinoma

Indexed keywords

GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; SIRTINOL; SIRTUIN 1; BENZAMIDE DERIVATIVE; DEOXYCYTIDINE; DRUG DERIVATIVE; NAPHTHOL DERIVATIVE; SIRT1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CARCINOMA; SURVIVAL RATE; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; DRUG COMBINATION; IMMUNOHISTOCHEMISTRY; INHIBITION OF SIRT1-GEMCITABINE; NUDE MOUSE; PANCREAS TUMOR; POLYACRYLAMIDE GEL ELECTROPHORESIS; SURVIVAL; THERAPY; TUMOR CELL LINE; WESTERN BLOTTING;

COMBINATION THERAPY; INHIBITION OF SIRT1-GEMCITABINE; PANCREATIC CARCINOMA;

ANIMALS; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NAPHTHOLS; PANCREATIC NEOPLASMS; SIRTUIN 1; SURVIVAL ANALYSIS;

EID: 84880317987     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S45064     Document Type: Article

References (27)

1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049-1057.
2. Zhou J, Song SD, Li DC, Zhou J, Zhu DM, Zheng SY. Clinical significance of expression and amplification of the DcR3 gene in pancreatic carcinoma. Asian Pac J Cancer Prev. 2012;13(2):719-724.
3. Ikeda S, Maeshirok K, Ryu S, et al. Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography: an analysis of 29 patients. Pancreas. 2009;38(4):102-113.
4. Klauss M, Stiller W, Fritz F, et al. Computed tomography perfusion analysis of pancreatic carcinoma. J Comput Assist Tomogr. 2012;36(2): 237-242.
5. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997;15(6): 2403
6. Burris H, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist. 2008;13(3): 289-298
7. O'Reilly EM, Abou-Alfa GK. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol. 2007;34(4):347-353.
8. von Wichert G, Seufferlein T, Adler G. Palliative treatment of pancreatic cancer. J Dig Dis. 2008;9(1):1-7.
9. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26(37):5420-5432.
10. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007;26(37):5489-5504.
11. Hida Y, Kubo Y, Murao K, Arase S. Strong expression of a longevity related protein, SIRT1, in Bowen's disease. Arch Dermatol Res. 2007; 299(2):103-106.
12. Huffman DM, Grizzle WE, Bamman MM, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007;67(14): 6612-6618.
13. Kuzmichev A, Margueron R, Vaquero A, et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci U S A. 2005;102(6): 1859-1864.
14. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004;23(12):2369-2380.
15. Danovi SA, Wong HH, Lemoine NR. Targeted therapies for pancreatic cancer. Br Med Bull. 2008;87:97-130.
16. Kleespies A, Jauch KW, Bruns CJ. Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer? Drug Resist Updat. 2006;9(1-2):1-18.
17. Ko AH. Future strategies for targeted therapies and tailored patient management in pancreatic cancer. Semin Oncol. 2007;34(4): 354-364.
18. Parsels LA, Morgan MA, Tanska DM, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther. 2009;8(1):45-54.
19. VanWeelden K, Flanagan L, Binderup L, Tenniswood M, Welsh J. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology. 1998;139(4): 2102-2110
20. Ikejima M, Noguchi S, Yamashita R, et al. The zinc fingers of human poly(ADP-ribose) polymerase are differentially required for the recognition of DNA breaks and nicks and the consequent enzyme activation. Other structures recognize intact DNA. J Biol Chem. 1990;265(35): 1907-21913.
21. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res. 1993;53(17): 3976-3985.
22. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature. 1994;371(6495):346-347.
23. Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell. 1995;81(5): 801-819
24. Yokoyama Y, Nimura Y, Nagino M. Advances in the treatment of pancreatic cancer: limitations of surgery and evaluation of new therapeutic strategies. Surg Today. 2009;39(6):466-475.
25. Pliarchopoulou K, Pectasides D. Pancreatic cancer: current and future treatment strategies. Cancer Treat Rev. 2009;35(5):431-436.
26. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-160.
27. Kalle AM, Mallika A, Badiger J, Alinakhi, Talukdar P, Sachchidanand. Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells. Biochem Biophys Res Commun. 2010;401(1):13-19.